Please enable Javascript
The HemOnc Pulse
Meeting News
The HemOnc Pulse Live
Video Insights
In Print
Subscribe
Leukemia
Acute Lymphoblastic Leukemia
Acute Myeloid Leukemia
Chronic Lymphocytic Leukemia
Chronic Myeloid Leukemia
Lymphoma
Aggressive B-Cell Lymphoma
Hodgkin Lymphoma
Indolent B-Cell Lymphoma
Mantle Cell Lymphoma
T-Cell Lymphoma
MPN
Myelofibrosis
Polycythemia Vera
MDS
Myeloma
Transplantation & Cellular Therapy
Melissa Badamo
Melissa Badamo is an associate editor for
Blood Cancers Today.
Articles by Melissa Badamo
Incidental Follicular Lymphoma Diagnosis Associated With Earlier-Stage Disease
Melissa Badamo
Follicular Lymphoma
|
July 8, 2025
The study investigated the role of multi-cancer early detection tests (MCEDs) on patient survival outcomes.
Read More
Bridging the Gap: NCCN Summit Advocates for Primary Care and Oncology Collaboration to Improve Patient Outcomes
Melissa Badamo
Acute Lymphoblastic Leukemia
|
July 7, 2025
Gaps in coordination and collaboration between primary care and oncology may impact long-term survival outcomes for patients.
Read More
FDA Fast Tracks SGR-1505 for Relapsed Waldenström Macroglobulinemia
Melissa Badamo
Waldenstrom's Macroglobulinemia
|
July 8, 2025
SGR-1505 has shown promising efficacy and safety in an ongoing, phase 1 dose-escalation study.
Read More
Menin Inhibitor Revumenib Under FDA Priority Review for Relapsed or Refractory NPM1-Mutated AML
Melissa Badamo
Acute Myeloid Leukemia
|
July 1, 2025
Revumenib has received FDA Priority Review with a Prescription Drug User Fee Act target action date of October 25, 2025.
Read More
Dr. Gabriel Mannis Shares TUSCANY Trial Results of Tuspetinib Triplet in AML
Melissa Badamo
Acute Myeloid Leukemia
|
July 1, 2025
Tuspetinib plus standard of care venetoclax and azacitidine in newly-diagnosed AML showed promising safety and efficacy.
View More
BRCA Mutations Linked to Higher Risk of Rare T-Cell Lymphoma for Women With Breast Cancer With Textured Implants
Melissa Badamo
T-Cell Lymphoma
|
July 1, 2025
Paola Ghione, MD, discusses these findings and how breast implant-associated anaplastic large cell lymphoma is managed.
View More
PTCL Treatment Combination Offers Promising Bridging Strategy to Allogeneic HSCT
Melissa Badamo
T-Cell Lymphoma
|
July 1, 2025
11 of 17 patients who achieved a complete or partial response were able to bridge to HSCT.
View More
Study Outlines Real-World Efficacy of Duvelisib Plus Romidepsin in Patients With PTCL
Melissa Badamo
T-Cell Lymphoma
|
July 1, 2025
Josie Ford, of Mass General Hospital, shared real-world efficacy and safety data on duvelisib and romidepsin in PTCL.
View More
FDA OKs Tafasitamab Combo for Relapsed Follicular Lymphoma
Melissa Badamo
Follicular Lymphoma
|
June 25, 2025
The approval of tafasitamab-cxix in combination with rituximab and lenalidomide was based on the phase 3 inMIND trial.
Read More
FDA Grants Orphan Drug Designation to SENTI-202 for Relapsed or Refractory AML and MDS
Melissa Badamo
Acute Myeloid Leukemia
|
June 24, 2025
SENTI-202, a first-in-class, off-the-shelf, logic-gated CAR-NK cell therapy, is currently being evaluated in a phase 1 trial.
Read More
Get to Know...Bhavana Bhatnagar, DO
Melissa Badamo
Acute Myeloid Leukemia
|
June 24, 2025
Dr. Bhatnagar shared her research interests on rural disparities in AML and her experience working in a community setting.
Read More
June 2025
This issue of Blood Cancers Today includes a feature on AI in oncology, a Get to Know with Bhavana Bhatnagar, DO, and more.
Read More
Novel Combination Exceeds Standard Therapy for Relapsed or Refractory Multiple Myeloma
Melissa Badamo
Myeloma
|
June 16, 2025
Talquetamab plus teclistamab yields high responses in patients with relapsed/refractory myeloma and extramedullary disease.
Read More
Dr. Peter Voorhees on T-Cell Fitness and the Potential of Cilta-Cel in Earlier Lines of Therapy
Melissa Badamo
Myeloma
|
June 13, 2025
The ratio of T cells to neutrophils at the time of leukapheresis was associated with better outcomes, Dr. Voorhees explained.
View More
Phase 3 IMROZ Trial Spotlights Isa-VRd Survival Benefit for Patients With Newly Diagnosed Myeloma
Melissa Badamo
Myeloma
|
June 16, 2025
Isatuximab added to bortezomib, lenalidomide, and dexamethasone showed a significant PFS benefit in myeloma.
Read More
Dr. Peter Voorhees Shares ‘Impressive Results’ From CARTITUDE-1 Trial in Myeloma
Melissa Badamo
Myeloma
|
June 10, 2025
At 5 years, 33% of patients with myeloma receiving cilta-cel in the CARTITUDE-1 trial are alive and disease free.
View More
Dr. Ruben Mesa on the SURPASS-ET Trial and Unmet Needs in Essential Thrombocythemia
Ruben A. Mesa, MD
Myeloproliferative Neoplasms
|
July 7, 2025
The phase 3 SURPASS-ET trial presented at ASCO evaluated ropeginterferon alfa-2b versus anagrelide for the treatment of ET.
View More
Acalabrutinib Combination Improves PFS in Previously Untreated MCL
Melissa Badamo
Mantle Cell Lymphoma
|
June 6, 2025
Acalabrutinib plus bendamustine-rituximab is a new standard therapy for patients 65 years or older with untreated MCL.
Read More
Odronextamab Shows Durable Response in Relapsed Follicular Lymphoma
Melissa Badamo
Follicular Lymphoma
|
June 3, 2025
Of 128 efficacy-evaluable patients, the ORR was 80.5% and the CR rate was 74.2% at a median follow-up of 28.3 months.
Read More
HMA-HDAC Combination Safe and Feasible in Patients With AML and MDS After HSCT
Melissa Badamo
Myelodysplastic Syndromes
|
June 10, 2025
Azacitidine plus valproic acid is a safe and feasible maintenance regimen for patients with high-risk AML and MDS after HSCT.
Read More
Load More